A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Aclaris Therapeutics, Inc.
ACRS
$641M
Mkt Cap
$5.23
-4.56%
Aclaris Therapeutics, Inc. (ACRS) has a 5-year average return on invested capital (ROIC) of -58.4%. This is below average and may indicate limited pricing power.
Aclaris Therapeutics, Inc. (ACRS) has a market capitalization of $641M. It is classified as a small-cap stock.
Aclaris Therapeutics, Inc. (ACRS) does not currently pay a regular dividend.
Aclaris Therapeutics, Inc. (ACRS) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Aclaris Therapeutics, Inc. (ACRS) generated $-47 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Aclaris Therapeutics, Inc. (ACRS) has a debt-to-equity ratio of 0.56. This indicates moderate leverage.
Aclaris Therapeutics, Inc. (ACRS) reported earnings per share (EPS) of $-0.53 in its most recent fiscal year.
Aclaris Therapeutics, Inc. operates in the Pharmaceutical Preparations industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | - |
| Net Income | -65M | -65M | -132M | -88M | -87M | -91M |
| EPS | $-0.53 | $-0.53 | $-1.71 | $-1.27 | $-1.33 | $-1.60 |
| Free Cash Flow | -47M | -47M | -20M | -80M | -68M | -52M |
| ROIC | -72.6% | -63.0% | -84.9% | -56.3% | -44.0% | -43.7% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.56 | 0.42 | 0.26 | 0.29 | 0.05 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -76M | -76M | -142M | -97M | -90M | -90M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -63.0% | -50.2% | -84.9% | -56.3% | -44.0% | -46.0% |
| Shares Outstanding | 122M | 122M | 77M | 70M | 65M | 57M |
| Metric | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 15M | 40M | 61M | 65M | 29M | 44M | 78M | 98M | 34M | 53M | 53M |
| SG&A | 5.3M | 19M | 26M | 28M | 21M | 24M | 25M | 32M | 22M | 22M | 22M |
| EBIT | -21M | -72M | -85M | -111M | -51M | -90M | -90M | -97M | -142M | -76M | -76M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -23M | -69M | -133M | -161M | -51M | -91M | -87M | -88M | -132M | -65M | -65M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 19M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||||||
| ROIC | -22.0% | -30.4% | -54.2% | N/M | -56.8% | -43.7% | -44.0% | -56.3% | -84.9% | -63.0% | -72.6% |
| ROE | N/A | -30.4% | -61.7% | -230.8% | -135.5% | -46.0% | -44.0% | -56.3% | -84.9% | -50.2% | -63.0% |
| ROA | -41.5% | -28.1% | -48.2% | -164.1% | -72.1% | -36.2% | -34.1% | -44.8% | -59.9% | -34.1% | -40.5% |
| Cash Flow | |||||||||||
| Op. Cash Flow | -20M | -55M | -101M | -96M | -39M | -52M | -68M | -78M | -20M | -47M | -47M |
| Free Cash Flow | -21M | -56M | -102M | -98M | -39M | -52M | -68M | -80M | -20M | -47M | -47M |
| Owner Earnings | -21M | -69M | -123M | -119M | -51M | -67M | -83M | -100M | -32M | -60M | -60M |
| CapEx | 507K | 1.2M | 1.4M | 1.6M | 453K | 308K | 605K | 1.3M | 121K | 111K | 111K |
| Maint. CapEx | 90K | 402K | 1.9M | 6.4M | 1.3M | 923K | 797K | 863K | 807K | 454K | 454K |
| Growth CapEx | 417K | 833K | 0 | 0 | 0 | 0 | 0 | 446K | 0 | 0 | 0 |
| D&A | 90K | 402K | 1.9M | 6.4M | 1.3M | 923K | 797K | 863K | 807K | 454K | 454K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 891K | 14M | 20M | 16M | 11M | 14M | 15M | 21M | 11M | 12M | 12M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||||
| Net Debt | N/A | N/A | -138M | -43M | -43M | -181M | N/A | N/A | N/A | N/A | -20M |
| Cash & Equiv. | 9.9M | 20M | 57M | 34M | 22M | 27M | 45M | 40M | 25M | 20M | 20M |
| Long-Term Debt | N/A | N/A | 30M | 30M | 11M | 11M | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | N/A | 0.08 | 0.14 | 0.43 | 0.28 | 0.05 | 0.29 | 0.26 | 0.42 | 0.56 | 0.00 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | N/A | 225M | 215M | 70M | 38M | 197M | 198M | 157M | 156M | 103M | 103M |
| Total Assets | 94M | 244M | 276M | 98M | 71M | 251M | 255M | 197M | 220M | 160M | 160M |
| Total Liabilities | N/A | 18M | 60M | 28M | 33M | 54M | 57M | 40M | 65M | 57M | 57M |
| Intangibles | 1.6M | 26M | 26M | 14M | 14M | 14M | 14M | 269K | N/A | N/A | N/A |
| Retained Earnings | -43M | -159M | -292M | -454M | -505M | -595M | -682M | -771M | -903M | -968M | -968M |
| Working Capital | 85M | 187M | 152M | 61M | 43M | 182M | 210M | 98M | 94M | 68M | 68M |
| Current Assets | 87M | 200M | 179M | 84M | 57M | 205M | 232M | 129M | 126M | 96M | 96M |
| Current Liabilities | 1.6M | 13M | 27M | 22M | 15M | 23M | 22M | 31M | 32M | 29M | 29M |
| Per Share Data | |||||||||||
| EPS | -3.79 | -2.44 | -4.03 | -3.90 | -1.20 | -1.60 | -1.33 | -1.27 | -1.71 | -0.53 | -0.53 |
| Owner EPS | -1.06 | -2.47 | -3.73 | -2.88 | -1.20 | -1.18 | -1.28 | -1.43 | -0.41 | -0.49 | -0.49 |
| Book Value | N/A | 8.02 | 6.53 | 1.69 | 0.89 | 3.47 | 3.02 | 2.26 | 2.01 | 0.84 | 0.84 |
| Cash Flow/Share | -1.01 | -1.95 | -3.06 | -2.33 | -0.91 | -0.92 | -1.03 | -1.12 | -0.26 | -0.38 | -0.53 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 20.2M | 28.1M | 32.9M | 41.4M | 42.5M | 56.8M | 65.3M | 69.7M | 77.2M | 122.5M | 122.5M |
| Valuation | |||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -9.9 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 3.1 | 1.1 | 1.1 | 7.6 | 4.2 | 5.1 | 0.5 | 1.4 | 3.6 | 6.2 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | -3.6% | -7.9% | -42.4% | -123.4% | -13.7% | -6.3% | -6.7% | -106.8% | -9.6% | -12.7% | -7.4% |
| Market Cap | 580M | 706M | 241M | 79M | 286M | 831M | 1.0B | 75M | 211M | 371M | 641M |
| Avg. Price | 19.02 | 26.80 | 16.85 | 3.79 | 2.25 | 18.19 | 14.87 | 8.43 | 1.52 | 1.93 | 5.23 |
| Year-End Price | 28.78 | 25.14 | 7.31 | 1.92 | 6.72 | 14.64 | 15.49 | 1.07 | 2.73 | 3.03 | 5.23 |
Aclaris Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Aclaris Therapeutics, Inc. (ACRS) has a return on equity (ROE) of -50.2%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 10 years of financial data for Aclaris Therapeutics, Inc. (ACRS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Aclaris Therapeutics, Inc. (ACRS) has a book value per share of $0.84, based on its most recent annual SEC filing.